Pharmaceutical Sales: 100% (2025)

TOP 3 Markets:

1. USA: approx. 45%
2. Europe (including Germany, France, UK): approx. 35%
3. Japan: approx. 10%

UCB SA is a biopharmaceutical company, with revenues entirely derived from the pharmaceutical industry. The USA represents the largest single market, followed by Europe, which as a region accounts for a significant portion of sales. Japan is also an important market, making a substantial contribution to the total revenue. This distribution reflects UCB's global presence and focus on key international markets.

Production sites of UCB SA:

1. Braine-l'Alleud, Belgium
2. Bulle, Switzerland
3. Raleigh, USA
4. Suzhou, China

UCB SA is a globally active biopharmaceutical company headquartered in Brussels, Belgium. The production facilities are strategically located in different regions to ensure supply security and proximity to key markets. Braine-l'Alleud is home to one of the largest production plants focusing on the manufacturing of biopharmaceuticals. The facility in Bulle is known for the production of biological active substances. Raleigh and Suzhou also carry out important production processes to serve the North American and Asian markets.

Focus on Research and Development: 25% of revenue (2024)

Planned Market Launches: 3 new drugs by 2026

Investments in Biotechnology: 500 million euros (2023-2025)

UCB SA pursues a growth strategy that is strongly focused on research and development (R&D). The company invests around 25% of its revenue in R&D to expand its pipeline of innovative drugs. These investments aim to develop new therapies in areas such as immunology and neurology.

By 2026, UCB plans to launch three new drugs that are currently in the late stage of development. These products are intended to complement the existing portfolio and drive revenue growth.

Furthermore, UCB is increasing its investments in biotechnology, with a planned investment volume of 500 million euros from 2023 to 2025. These investments are aimed at expanding production capacities and increasing efficiency in the manufacturing of biological drugs.

Main raw materials: Chemicals, biological materials

Countries of origin: USA, Germany, China

UCB SA, a globally active biopharmaceutical company, imports a variety of raw materials necessary for the production of their medicines and biopharmaceutical products. The most important materials include specialized chemicals and biological materials used in research and production.

The USA is a significant supplier of advanced chemical components needed in the pharmaceutical industry. Germany also provides high-quality chemical and biological materials crucial for the manufacturing of medicines. China is another important partner, especially for cost-effective chemical raw materials and commodities.

These import strategies enable UCB to produce high-quality products at competitive prices while ensuring supply security.

Market share in neurology: 20% (2024, estimated)
Research & Development (R&D) expenses: 1.5 billion euros (2024)
Patent portfolio: Over 1000 active patents (2024)

UCB SA has a significant competitive advantage, especially in the field of neurology, where the company holds an estimated market share of 20%. This is due to their specialized medications and a strong pipeline of products in development.

The company continuously invests significant amounts in research and development, with expenses of 1.5 billion euros in 2024, which is approximately 25% of the revenue. These investments strengthen UCB's innovation capabilities and secure their market position in the long term.

Another element of the competitive advantage is the extensive patent portfolio with over 1000 active patents, which provides UCB with protection against imitation products and ensures the exclusivity of their products in the market.

Institutional investor share: Approx. 70% (estimated for 2025 based on historical data)

Insider trades: No significant transactions in the last year (2024)

UCB SA has traditionally had a high institutional investor share, which has hovered around 70% in recent years. This reflects the confidence of large investors in the company's stability and growth potential.

In 2024, there were no significant insider transactions, indicating a stable internal assessment of the company's development. Insider buys or sells are often seen as indicators of management's confidence in the company's future performance.

Market share of UCB SA: Estimated 3-5% in the global pharmaceutical market (2025)

Main competitors and their market share:

1. Pfizer Inc.: 10-12%
2. Roche Holding AG: 8-10%
3. Novartis AG: 8-10%
4. Johnson & Johnson: 7-9%
5. Merck & Co., Inc.: 6-8%
6. Sanofi: 5-7%
7. GlaxoSmithKline plc: 4-6%
8. AstraZeneca plc: 4-6%
9. Bristol-Myers Squibb: 3-5%
10. UCB SA: 3-5%

UCB SA is a medium-sized company in the global pharmaceutical market with a specialized focus on neurology and immunology. UCB's moat mainly lies in its strong research and development department, which produces innovative drugs in these areas.

Compared to the largest competitors, which have more extensive product portfolios and greater financial resources, UCB's moat is less pronounced. Companies like Pfizer and Roche have a stronger moat due to their size and diversification, as they are able to better distribute risks and make larger investments in research and development.

However, through its specialization and niche strategy in certain therapeutic areas, UCB can achieve competitive advantages that allow it to compete against larger competitors.

Revenue growth: 8% (2024) R&D expenses: 25% of revenue (2024) New product approvals: 3 significant approvals (2024)

UCB SA recorded a revenue growth of 8% in 2024, attributed to successful market launches of new products and a strong pipeline. The company continues to heavily invest in research and development, with expenses accounting for 25% of revenue. These investments underscore UCB's commitment to innovation and long-term growth.

In 2024, UCB received three significant new product approvals, increasing the potential for future revenue growth. These developments could position the company advantageously in the competition, especially in the areas where the new products were introduced.

Given these factors, UCB SA could present an attractive investment opportunity, especially for investors focusing on long-term growth and innovation. However, analysts may also consider the risks associated with the implementation of product strategies and market dynamics.

Dividend yield: 1.8% (2024)

UCB SA recorded a dividend yield of 1.8% in 2024. The company has a tradition of regularly paying dividends, indicating a certain level of reliability.

In recent years, UCB SA has consistently increased its dividend, suggesting solid financial health and a stable business model. Analysts believe that the company will also be able to pay dividends in the coming years, provided that no significant negative market changes occur.